岗位职责
Select the most appropriate animal model(s) to validate molecular and cellular targets, leading to increased understanding of the disease process. Study, design, conduct, and report in vivo studies for lead optimization of novel agents affecting signaling pathways.
Responsible for complex architecture director and activitie design for In Vivo biology discovery program. Drives and lead in-depth and leading edge research that has organizational-wide impact.Reviews and approves the architecture of projects at a higher or final level.
Responsible for complex architecture director and activitie design for In Vivo biology discovery program. Drives and lead in-depth and leading edge research that has organizational-wide impact.Reviews and approves the architecture of projects at a higher or final level.
任职要求
1. Directs and controls the activities of a broad functional areas through several department managers and having overall responsibility for planning budgeting, implementing processes, and maintaining cost
2. Drives and lead in-depth and leading edge research that has organizational-wide impact
3. Participate in strategic plans and objectives. Makes decisions on administrative and operational matters and ensures operations effective achievement of objectives
2. Drives and lead in-depth and leading edge research that has organizational-wide impact
3. Participate in strategic plans and objectives. Makes decisions on administrative and operational matters and ensures operations effective achievement of objectives
公司基本信息
性质：外资企业
行业：科学研究和技术服务业
规模：微型（<10人）
地址：苏州工业园区星湖街218号生物医药产业园B5楼501单元
公司概况
维亚臻成立于2022年，并与国际领先的小核酸药物企业Arrowhead Pharmaceuticals(NASDAQ:ARWR)建立战略合作关系。目前公司产品管线拥有三款处于临床研发阶段、针对心血管及代谢领域的小核酸(siRNA)药物。此外，公司拥有自主研发能力，将在肝内及肝外递送技术、以及更广阔的治疗领域进行探索。
公司现有管线在同类竞品中处于领先位置，其靶点具有明确的基因组学及生物学证据支持，使用Arrowhead已经验证的递送及化学修饰技术平台。公司采用中美协同的临床开发及注册策略，有助于加速产品上市。
公司的内部研发能力将进一步丰富包括心血管及代谢领域在内的临床研发管线，实现公司的长期可持续发展，同时通过内外部资源形成从研发、生产至销售的全产业链布局。
公司现有管线在同类竞品中处于领先位置，其靶点具有明确的基因组学及生物学证据支持，使用Arrowhead已经验证的递送及化学修饰技术平台。公司采用中美协同的临床开发及注册策略，有助于加速产品上市。
公司的内部研发能力将进一步丰富包括心血管及代谢领域在内的临床研发管线，实现公司的长期可持续发展，同时通过内外部资源形成从研发、生产至销售的全产业链布局。
返回
顶部
顶部